Trial · NCT01173679
Adverse events82
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 82
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Dasatinib, Rituximab, Fludarabine | 5 | 10 | 18 |
| other | Anemia | Blood and lymphatic system disorders | Dasatinib, Rituximab, Fludarabine | 5 | 10 | 14 |
| other | Platelet count decreased | Investigations | Dasatinib, Rituximab, Fludarabine | 5 | 10 | 14 |
| other | Nausea | Gastrointestinal disorders | Dasatinib, Rituximab, Fludarabine | 5 | 10 | 7 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Dasatinib, Rituximab, Fludarabine | 4 | 10 | 12 |
| other | White blood cell decreased | Investigations | Dasatinib, Rituximab, Fludarabine | 4 | 10 | 11 |
| other | Blood bilirubin increased | Investigations | Dasatinib, Rituximab, Fludarabine | 4 | 10 | 9 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dasatinib, Rituximab, Fludarabine | 4 | 10 | 9 |
| other | Chills | General disorders | Dasatinib, Rituximab, Fludarabine | 4 | 10 | 8 |
| other | Hyperglycemia | Metabolism and nutrition disorders | Dasatinib, Rituximab, Fludarabine | 4 | 10 | 8 |
| other | Neutrophil count decreased | Investigations | Dasatinib, Rituximab, Fludarabine | 4 | 10 | 5 |
| other | Diarrhea | Gastrointestinal disorders | Dasatinib, Rituximab, Fludarabine | 4 | 10 | 4 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Dasatinib, Rituximab, Fludarabine | 3 | 10 | 4 |
| other | General disorders and administration site conditions - Other, specify | General disorders | Dasatinib, Rituximab, Fludarabine | 3 | 10 | 4 |
| other | Abdominal pain | Gastrointestinal disorders | Dasatinib, Rituximab, Fludarabine | 3 | 10 | 4 |
| other | Hypophosphatemia | Metabolism and nutrition disorders | Dasatinib, Rituximab, Fludarabine | 3 | 10 | 3 |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Dasatinib, Rituximab, Fludarabine | 2 | 10 | 5 |
| other | Alkaline phosphatase increased | Investigations | Dasatinib, Rituximab, Fludarabine | 2 | 10 | 4 |
| other | Aspartate aminotransferase increased | Investigations | Dasatinib, Rituximab, Fludarabine | 2 | 10 | 4 |
| other | Edema limbs | General disorders | Dasatinib, Rituximab, Fludarabine | 2 | 10 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01173679/events